The scopolamine market is expected to grow at a CAGR of around 4.5% during the forecast period. Scopolamine is also known as Hyoscine that is majorly used to treat motion sickness & nausea and vomiting. It is an alkaloid drug that is extracted from the henbane plant. It is also used as a sedative and can be used along with the morphine to relieve pain. The drug requires a prescription and is not available as an over the counter drug.
Rise in the number of people suffering from stress and anxiety disorder is a major factor for the growth of the scopolamine drug market. Moreover, significant research in the field of Alzheimer’s disease treatment is also undergoing related scopolamine which can provide a significant opportunity to the drug if some positive results outcomes witnessed in the near future.
To Request a Sample of our Report on Global Scopolamine Market: https://www.omrglobal.com/request-sample/scopolamine-market
However, misuse of the drug for the illegal activities is one of the major challenge to the market as the government may strict the regulations related to the distribution of the drug. When scopolamine is mixed in the beverage of a person, it can cause a range of acute psychoses including hallucinations, disorientation, and paranoia. As an estimate, around 50,000 cases of poisoning of scopolamine are registered every year in the US and Colombia each. Moreover, the presence of alternative globally is a restraining factor for the market. Ondansetron, Promethazine, Prochlorperazine are some of the alternative drugs available in the market for the treatment of nausea and vomiting.
(Get 15% Discount on Buying this Report)
A full Report of Global Scopolamine Market is Available at: https://www.omrglobal.com/industry-reports/scopolamine-market
Global Scopolamine Market Segmentation
By Type
- Scopolamine Butyl bromide
- Scopolamine Base
By Dosage type
- Oral
- Patches
- Injections
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
